Kezar Life Sciences, Inc. (KZR)
May 11, 2026 - KZR was delisted (reason: acquired by AUPH)
7.29
0.00 (0.00%)
Inactive · Last trade price
on May 8, 2026
Company Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States.
The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus.
Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Kezar Life Sciences, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 21, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Christopher Kirk |
Contact Details
Address: 4000 Shoreline Court, Suite 300 South San Francisco, California 94080 United States | |
| Phone | 650 822 5600 |
| Website | kezarlifesciences.com |
Stock Details
| Ticker Symbol | KZR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645666 |
| CUSIP Number | 49372L100 |
| ISIN Number | US49372L2097 |
| Employer ID | 47-3366145 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher J. Kirk Ph.D. | Co-Founder, Chief Executive Officer and Director |
| John Franklin Fowler | Co-Founder and Director |
| Mark Schiller | Chief Operations Officer |
| Dr. Jack Taunton Ph.D. | Co-Founder |
| Pichi Chiang | Senior Vice President and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2026 | SCHEDULE 13G/A | Filing |
| May 12, 2026 | SCHEDULE 13G/A | Filing |
| May 11, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 11, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 11, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 11, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 11, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 11, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 11, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| May 11, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |